Greater Cannabis Company (GCAN) Change in Account Payables (2019 - 2026)
Greater Cannabis Company's (GCAN) quarterly Change in Account Payables came in at -$1000.0 in Q1 2026, down 706.06% year-on-year from $165.0 in Q1 2025, and down 198.51% quarter-over-quarter from -$335.0 in Q4 2025.
Greater Cannabis Company (GCAN) Change in Account Payables (2019 - 2026) Analysis & Trends
Greater Cannabis Company's Change in Account Payables history runs 8 years deep, the most recent figure standing at -$1000.0 for Q1 2026.
- On a quarterly basis, Change in Account Payables fell 706.06% year-over-year to -$1000.0 in Q1 2026; TTM through Mar 2026 was -$530.0, a 129.69% decrease from a year earlier, with the FY2025 full-year figure at $635.0, down 64.43% from the prior year.
- Change in Account Payables fell to -$1000.0 in Q1 2026 per GCAN's latest filing, from -$335.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $5951.0 in Q3 2022 and bottomed at -$10259.0 in Q1 2023.
- The 5-year median for Change in Account Payables is $165.0 (2024), against an average of -$246.53.
- Across the five-year window, Change in Account Payables plunged 920.72% in 2023 and soared 157.95% in 2024, its largest moves.
- Year by year, Change in Account Payables stood at $1954.0 in 2022, then surged by 40.94% to $2754.0 in 2023, then slumped by 46.95% to $1461.0 in 2024, then sank by 122.93% to -$335.0 in 2025, then slumped by 198.51% to -$1000.0 in 2026.
- Per Business Quant, the three latest GCAN Change in Account Payables figures stand at -$1000.0 (Q1 2026), -$335.0 (Q4 2025), and $2056.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -335.00 |
| Dec 31, 2025 | -335.00 |
| Sep 30, 2025 | 2,056.00 |
| Sep 30, 2025 | 2,056.00 |
| Jun 30, 2025 | -1,251.00 |
| Jun 30, 2025 | -1,251.00 |
| Mar 31, 2025 | 165.00 |
| Mar 31, 2025 | 165.00 |
| Dec 31, 2024 | 1,461.00 |
| Dec 31, 2024 | 1,461.00 |
| Sep 30, 2024 | 1,159.00 |
| Sep 30, 2024 | 1,159.00 |
| Jun 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -1,000.00 |
| Mar 31, 2024 | 165.00 |
| Mar 31, 2024 | 165.00 |
| Dec 31, 2023 | 2,754.00 |
| Dec 31, 2023 | 2,754.00 |